Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma

FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma

(2016) Aldwin Suryo Rahmanto et al.   EMBO JOURNAL

Divergent clonal selection dominates medulloblastoma at recurrence

(2016) A. Sorana Morrissy et al.   NATURE

Myc and cell cycle control

(2015) Gabriel Bretones et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease

(2015) Rebecca M. Hill et al.   CANCER CELL

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma

(2015) Anton George Henssen et al.   Oncotarget

Therapeutic Strategies to Inhibit MYC

(2014) M. R. McKeown et al.   Cold Spring Harbor Perspectives in Medicine

NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma

(2014) Giulio Fiaschetti et al.   Acta Neuropathologica Communications

Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier

(2013) C Albanese et al.   BRITISH JOURNAL OF PHARMACOLOGY

Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor

(2013) T K Albert et al.   BRITISH JOURNAL OF PHARMACOLOGY

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

(2013) Jakob Lovén et al.   CELL

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma

(2013) Z. Cheng et al.   CLINICAL CANCER RESEARCH

BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

(2013) P. Bandopadhayay et al.   CLINICAL CANCER RESEARCH

Stem Cells Expanded from the Human Embryonic Hindbrain Stably Retain Regional Specification and High Neurogenic Potency

(2013) J. Tailor et al.   JOURNAL OF NEUROSCIENCE

Oncoprotein stabilization in brain tumors

(2013) S-M Hede et al.   ONCOGENE

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

(2013) Alexandre Puissant et al.   Cancer Discovery

Role of MYC in Medulloblastoma

(2013) M. F. Roussel et al.   Cold Spring Harbor Perspectives in Medicine

Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC

(2012) Fredrik J. Swartling et al.   CANCER CELL

Recent Therapeutic Advances for Treating Medulloblastoma: Focus on New Molecular Targets

(2012) A.L. Schmidt et al.   CNS & Neurological Disorders-Drug Targets

The bromodomain interaction module

(2012) Panagis Filippakopoulos et al.   FEBS LETTERS

Subgroup-specific structural variation across 1,000 medulloblastoma genomes

(2012) Paul A. Northcott et al.   NATURE

Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks

(2012) Cole Trapnell et al.   Nature Protocols

MYC Is Activated by USP2a-Mediated Modulation of MicroRNAs in Prostate Cancer

(2012) Barbara Benassi et al.   Cancer Discovery

Multiple CDK/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumor

(2012) Meihua Li et al.   Cancer Genetics

MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma

(2011) Sarra L. Ryan et al.   ACTA NEUROPATHOLOGICA

Molecular subgroups of medulloblastoma: the current consensus

(2011) Michael D. Taylor et al.   ACTA NEUROPATHOLOGICA

Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

(2011) Glen J. Weiss et al.   INVESTIGATIONAL NEW DRUGS

Transcriptomes of the B and T Lineages Compared by Multiplatform Microarray Profiling

(2011) M. W. Painter et al.   JOURNAL OF IMMUNOLOGY

Pleiotropic role for MYCN in medulloblastoma

(2010) F. J. Swartling et al.   GENES & DEVELOPMENT

Subtypes of medulloblastoma have distinct developmental origins

(2010) Paul Gibson et al.   NATURE

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and theMYCandMYCNLoci

(2009) Stefan Pfister et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification ofN,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor

(2009) Maria Gabriella Brasca et al.   JOURNAL OF MEDICINAL CHEMISTRY

The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound

(2009) Simona Caporali et al.   PHARMACOLOGICAL RESEARCH

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells

(2009) J. J. Molenaar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation

(2009) P. Hydbring et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features

(2008) Marcel Kool et al.   PLoS One